In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra achieved completely clear skin by week 24.
All News
Advertisement
The latest news for pharma industry insiders.
Advertisement
Financing of Merida Biosciences was backed by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with participation from multiple other investors.
Davidi Vortman, CEO, UltraSight, discusses how AI-powered heart scan technology can help high-risk cardiovascular disease patients.
The latest news for pharma industry insiders.
The company announced a new CFO along with the creation of a new role, chief medical officer.
Advertisement
PharmaLogic states that the acquisition of Agilera Pharma AS will place the company in a unique global role in radiopharmaceutical production and distribution.
Approval of the Opdivo plus Yervoy combination regimen was based on results from the Phase III CheckMate-8HW trial, which was the largest immunotherapy study in patients with previously untreated, unresectable, or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.
Brimochol PF, a combination of brimonidine and carbachol, was found to enhance depth of focus and visual acuity in clinical trials among patients with presbyopia.
The latest news for pharma industry insiders.
Advertisement
The survey also suggests that Medicaid is broadly popular amongst all Americans, regardless of political affiliation.
“We’re going to tariff our pharmaceuticals, and once we do that, they are going to come rushing back into our country," President Donald J. Trump said during a Tuesday night dinner in Washington.
Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm autoimmune hemolytic anemia and IgG4-related disease.
The latest news for pharma industry insiders.
Family caregivers with both children and elderly family members to care for are reporting higher levels of burnout and mental health issues.
Results from the Phase III SPACE trial show that Ajovy significantly reduced monthly migraines in pediatric patients between six and 17 years of age.
Enrollment for the Phase II trial follows FDA clearance of SPG302 Investigational New Drug application for schizophrenia.
The latest news for pharma industry insiders.
Muscle loss is a serious issue for a number of patients, including those on GLP-1s.
The I LUVY YA for The Long Haul campaign features stories about the emotional impact of the disease.
Eli Lilly CEO David Ricks to the BBC: “It feels like it'll be hard to come back from here."
The latest news for pharma industry insiders.
Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 weeks in patients with primary immunoglobulin A nephropathy.
Results from the Phase III ZENITH trial show that Winrevair lowered the risk of all-cause death, lung transplantation, and pulmonary arterial hypertension-related hospitalization by 76%.
Results from the SOLARIS trial survey showed that over 92% of patients, 87% of nurses, and 72% of physicians expressed satisfaction with TEV-'749’s initiation regimen, dosing schedule, and overall treatment experience.
The line-up consists of supplements to meet the health needs to patients taking GLP-1 medications for weight loss.
The latest news for pharma industry insiders.
BIIB080 marks the first antisense oligonucleotide targeting tau to enter clinical development for the treatment of Alzheimer disease.
Charles River Laboratories will work directly with the platform.
The latest news for pharma industry insiders.
Advertisement
Advertisement
Trending on PharmExec
1
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
2
Roundup: AbbVie & Lambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM
3
Understanding the Latest with MFN Pricing and What It Means to Pharma
4
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
5